Drug Trial Radar · NCT01353313
Hydrocortisone for BPD
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Aug 11, 2011
Primary completion
Sep 21, 2020
Study completion Sep 12, 2024
Sponsor
- Lead sponsor
- NICHD Neonatal Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Center for Research Resources (NCRR); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); National Center for Advancing Translational Sciences (NCATS)
- First posted
- May 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 30 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.
Conditions
- Infant, Newborn
- Infant, Small for Gestational Age
- Infant, Very Low Birth Weight
- Infant, Premature
- Bronchopulmonary Dysplasia
Interventions
HydrocortisoneDrug
Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows: 4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then 1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
PlaceboDrug
Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows: 4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then 1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD)Time frame: From day of randomization to 36 weeks post menstrual age
- Survival Without Moderate/Severe Neurodevelopmental Impairment (NDI)Time frame: From day of randomization to 22-26 months corrected age
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California - Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
Emory University
Atlanta, Georgia
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Wayne State University
Detroit, Michigan
Children's Mercy Hospital
Kansas City, Missouri
University of New Mexico
Albuquerque, New Mexico
University of Rochester
Rochester, New York
RTI International
Durham, North Carolina
Duke University
Durham, North Carolina
Cincinnati Children's Medical Center
Cincinnati, Ohio
Case Western Reserve University, Rainbow Babies and Children's Hospital
Cleveland, Ohio
Research Institute at Nationwide Children's Hospital
Columbus, Ohio
Univeristy of Pennsylvania
Philadelphia, Pennsylvania
Brown University, Women & Infants Hospital of Rhode Island
Providence, Rhode Island
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
University of Texas Health Science Center at Houston
Houston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.